Viadevita: Clinical Studies
A human immune cell line, CEM, was utilized to test the product’s activity, at the National Cancer Institute (NCI) in Washington, D.C.
While almost a 75% recovery of the immune cells was obtained with AZT alone, more than 160% recovery was observed when Viadevita was added with AZT. Viadevita, therefore, was found to show a significant CEM cell growth, indicating its strong immune enhancing capability.
Twelve CDC Stage IV AIDS patients were recruited into a two-month interventional trial for Marromax to be taken up to three times daily. The course of their respective symptomatic clinical presentations was followed in addition to pre and post supplementation values of CBC, chemistry profile, selective vitamin screen (i.e., plasma folate, RBC folate, B12, Vit. C. Vit. A, beta-carotene, thiamine, and Vit. E), and immunologic marker studies in peripheral blood (i.e., WBC, lymphocytes, CD3, CD4, CD8). All patients were already receiving one or more antiviral drugs, usually AZT, and followed by their own physician. Each subject was seen for study follow up every two weeks for the two-month period.
|
PT. #
|
WT
|
BIO CHEM
|
HEMATOLOGIC
|
NUTRITIONAL
|
IMMUNOLOGIC
|
CLINICAL
|
|
1
|
+
|
S
|
S
|
SI
|
SI
|
+
|
|
2
|
+
|
S
|
S
|
+
|
-
|
+
|
|
3
|
+
|
-
|
-
|
+
|
-
|
+
|
|
4
|
-
|
S
|
+
|
+
|
+
|
+
|
|
5
|
+
|
SI
|
SI
|
+
|
+
|
+
|
|
6
|
+
|
SI
|
SI
|
+
|
+
|
+
|
|
7
|
+
|
+
|
S
|
+
|
+
|
+
|
|
8
|
+
|
+
|
+
|
+
|
+
|
+
|
|
9
|
+
|
+
|
+
|
+
|
SI
|
+
|
|
10
|
+
|
N/A
|
N/A
|
N/A
|
N/A
|
+
|
|
11
|
+
|
N/A
|
N/A
|
N/A
|
N/A
|
+
|
|
12
|
-
|
N/A
|
N/A
|
N/A
|
N/A
|
+
|
+ = Improved - = Deteriorated
S = Stable SI = Stable to Improved
N/A = Data Not Available
This table summarizes the biochemical and clinical responses descriptively in terms of improvement, deterioration, stable, or stable-to-improved conditions.
Subjects 1 - 9 completed the study fully. Subjects 10 and 11 did not return for post supplementation blood testing but did complete their clinical assessment follow up. Subject 12 interrupted the supplementation after 3 weeks when he was accepted by NIH to go to NIH for a study involving CMV therapy. He was available and wanting to return to this study at a later date. With respect to weight response 10/12 (83%) had variously a weight gain while 2/12 (16.7%) had weight loss. Subject number 4 lost weight near the last part of the intervention due to a severe flu like illness, which required several days in the hospital for treatment including rehydration.
> Dosage information
AIDS Facts Online
We've initiated the AIDS Facts area as a part of our website to help you learn more about this disease. We also suggest healthy living ideas including a sound diet, exercise and add a quality nutritional supplement to those currently living with HIV/AIDS.
